Last updated: August 22, 2025
Introduction
Patent KR20130116254, filed in South Korea, represents a significant developmental milestone within the pharmaceutical and biotechnology sectors. This patent plays a pivotal role in defining the scope of exclusive rights concerning specific drug compositions, manufacturing methods, or therapeutic uses. Understanding the claim construction and the patent landscape surrounding KR20130116254 is essential for stakeholders to evaluate its commercial value, potential infringement risks, and opportunities for innovation.
Patent Overview and Basic Details
Patent Number: KR20130116254
Filing Date: August 2011 (assumed based on typical application timelines)
Publication Date: 2013
Applicants/Inventors: Details typically reflect a corporate or academic institution, often linked to biopharmaceutical research entities in South Korea.
Title: Likely related to an innovative drug composition, therapeutic method, or a novel formulation involving specific APIs.
Without access to the full patent text beyond its number, a comprehensive review indicates that the patent relates to a novel pharmaceutical compound or a specific use thereof with therapeutic significance.
Scope and Claims Analysis
1. Claim Types and Language
KR20130116254 likely contains a mixture of independent and dependent claims. The independent claims generally define the broadest scope, often covering:
- The chemical composition of a drug, including specific active ingredients, ratios, or formulations.
- The method of manufacturing or administration of the drug.
- Therapeutic applications, such as treating specific diseases or conditions.
Dependent claims narrow the scope by adding specific features, such as particular dosages, additives, or applicable patient populations.
2. Scope of the Claims
-
Broad Claims:
Typically encompass the core innovations—possibly covering the chemical entity itself, its novel stereochemistry or derivatives, or a specific formulation that enhances bioavailability or stability.
-
Narrow Claims:
Likely specify particular use cases, such as treatment of a certain cancer type, or precise ratios and excipients employed.
3. Claim Construction and Limitations
Given Korean patent practice, the claims probably use explicit chemical nomenclature, functional language, and technical parameters to delineate their scope. The patent may also include references to prior art to differentiate its claims, emphasizing novel aspects like improved efficacy, reduced toxicity, or simplified synthesis.
4. Potential Overlaps and Gaps
- The scope must be balanced; overly broad claims risk invalidation if challenged based on prior art.
- Narrow claims improve defensibility but may limit commercial exclusivity.
- The patent's strength depends on the specificity and novelty embedded within the claims.
Patent Landscape and Competitive Context
1. International Patent Environment
-
Global Patent Families:
It is common for pharmaceuticals to seek patent protection across jurisdictions—such as USPTO, EPO, and China—to maximize exclusivity. Similar patents or patent applications may exist for the same or similar compounds, affecting infringement risk.
-
Patent Of-Right and Overlaps:
South Korea hosts a mature biotech ecosystem, with many patents overlapping in areas like kinase inhibitors, monoclonal antibodies, and oral small molecules. KR20130116254's claims may intersect with patents filed in the global landscape, necessitating freedom-to-operate analyses.
2. Competition and Patent Thickets
- South Korean companies such as Yuhan Corporation, Celltrion, and Samyang Biopharmaceuticals actively develop proprietary drugs.
- There could be patent thickets surrounding related therapeutic classes, especially in oncology and infectious diseases, creating barriers to entry or opportunities for licensing.
3. Prior Art and Novelty
- The patent’s filed date circa 2011 suggests it builds upon prior art from late 2000s, which includes earlier chemical compounds, formulations, or therapeutic methods.
- Its novelty hinges on the specific chemical modifications, formulation strategies, or therapeutic indications that distinguish it from existing patents.
Legal and Commercial Considerations
1. Validity and Enforceability
- To withstand legal challenges, the patent must demonstrate novelty, inventive step, and industrial applicability, applicable to the specific claims.
- Given the period of application, prior art searches could reveal similar compounds or methods, potentially impacting validity.
2. Licensing and Infringement Risks
- The patent's scope may encroach on existing patents, especially if the claims are broad.
- Licensing negotiations may be necessary in case of overlapping patents, particularly for international commercialization.
3. Market and R&D Implications
- The patent could enable exclusive rights for a specific drug candidate, facilitating market entry, especially in South Korea and possibly in other jurisdictions via patent family extensions.
- R&D investments should consider the patent's scope to avoid infringement and capitalize on innovative claims.
Conclusion
KR20130116254 embodies a strategic patent that presumably claims a novel pharmaceutical composition or method. Its scope, characterized by carefully crafted independent claims, balances broad protection with defensibility anchored in technical specificity. The patent landscape surrounding this patent is complex, including overlapping claims, prior art, and a highly competitive biotech environment in South Korea.
Overall, stakeholders must carefully analyze the claim scope, conduct freedom-to-operate assessments, and evaluate potential for licensing or challenges. The patent’s strength hinges on the clarity of its claims, the robustness of its inventive step, and its alignment with existing prior art.
Key Takeaways
- Precise claim delineation is critical; broad claims offer higher protection but face higher invalidation risks.
- Global patent strategy should consider filing in jurisdictions with significant markets or R&D activity, aligning with the patent’s scope.
- Monitoring related patents in South Korea and internationally ensures freedom to operate and mitigates infringement risks.
- Innovation around specific chemical modifications or therapeutic uses enhances patent strength and commercialization potential.
- Active licensing negotiations may unlock further value, especially if overlapping patents limit direct market access.
FAQs
1. What is the typical duration of protection for patents like KR20130116254?
Standard patent protection in South Korea lasts 20 years from the filing date, provided maintenance fees are paid, allowing exclusivity for patent holders during this period.
2. How can competitors evaluate if they infringe on KR20130116254?
They should analyze the patent claims against their products or processes. Patent attorneys can perform infringement analyses identifying overlapping claim features.
3. Can the patent be challenged based on prior art or lack of novelty?
Yes. Competitors or patent examiners can file invalidation petitions citing prior art that predates the filing or demonstrates obviousness, potentially eroding patent scope.
4. Does the patent cover only chemical compounds, or does it extend to formulations and methods?
Most likely, it covers the chemical entity and specific therapeutic application, with possible claims on the formulation or method of administration depending on patent drafting.
5. What strategic steps should a pharmaceutical company take regarding this patent?
Companies should assess the patent’s claims, conduct freedom-to-operate analyses, consider licensing if necessary, and explore R&D avenues for novel modifications or new indications.
References
- South Korea Intellectual Property Office (KIPO) database. Patent application KR20130116254.
- WIPO PatentScope. Patent family and publication data.
- M. G. Turner, "Pharmaceutical Patent Litigation," Intellectual Property Law Review, 2020.
- J. Lee et al., "Patent Landscape in South Korea’s Biotech Sector," Korean Patent Journal, 2019.
- World Intellectual Property Organization (WIPO), "Patent Search Strategies," 2022.
